| First results of DISCO RADIAL, a Terumo sponsored study | https://www.terumo-europe.com/en-emea/news/first-results-of-disco-radial-a-terumo-sponsored-study | First results of DISCO RADIAL, a Terumo sponsored study | LEUVEN, BELGIUM | 6/14/2022 10:00:00 PM | Late Breaking Trial presentation at EuroPCR 2022 with simultaneous publication in the Journal of the American College of Cardiology (JACC)<p><br></p> |
| Holmium-166 SIRT demonstrates safety and efficacy in the treatment of Hepatocellular carcinoma (HCC) | https://www.terumo-europe.com/en-emea/news/holmium-166-sirt-demonstrates-safety-and-efficacy-in-the-treatment-of-hepatocellular-carcinoma-(hcc) | Holmium-166 SIRT demonstrates safety and efficacy in the treatment of Hepatocellular carcinoma (HCC) | LEUVEN, BELGIUM | 6/13/2022 10:00:00 PM | <p>Terumo Europe N.V. is proud to share the latest clinical news regarding Holmium-166 (QuiremSpheres<sup>TM</sup> holmium-166 microspheres) Selective Internal Radiation Therapy (SIRT). On May 19, 2022, the UMC Utrecht published their latest results in the JNM 2022 from the HEPAR Primary study. The study evaluated the safety and efficacy of Holmium-166 SIRT in the treatment of HCC patients (BCLC stage B & C) without curative options. <br></p> |
| Terumo Appoints Three Associates as the Newest Terumo Fellow | https://www.terumo-europe.com/en-emea/news/terumo-appoints-three-associates-as-the-newest-terumo-fellow | Terumo Appoints Three Associates as the Newest Terumo Fellow | TOKYO, JAPAN | 6/6/2022 10:00:00 PM | <p>Contributing to Terumo Group’s Core Technology in Diabetes Care, ME Devices and Neurovascular Treatment <br></p> |
| Radboudumc and Terumo Europe N.V. sign collaboration agreement | https://www.terumo-europe.com/en-emea/news/radboudumc-and-terumo-europe-n-v-sign-collaboration-agreement | Radboudumc and Terumo Europe N.V. sign collaboration agreement | LEUVEN, BELGIUM | 6/1/2022 10:00:00 PM | <p>Radboudumc and Terumo Europe N.V. signed yesterday a strategic collaboration agreement. Together, the two partners will improve existing treatments for cancer patients and develop new, personalized therapies. Focus will be on the clinical use of holmium-166 microspheres, small radioactive beads.<br></p> |
| Terumo Pharmaceutical Solutions offers pre-fillable syringe solutions for demanding low dose applications such as ophthalmic | https://www.terumo-europe.com/en-emea/news/terumo-pharmaceutical-solutions-offers-pre-fillable-syringe-solutions-for-demanding-low-dose-applications-such-as-ophthalmi | Terumo Pharmaceutical Solutions offers pre-fillable syringe solutions for demanding low dose applications such as ophthalmic | LEUVEN, BELGIUM | 5/16/2022 10:00:00 PM | <p>Terumo Pharmaceutical Solutions (TPS), a division of Terumo Corporation (TSE: 4543) and a leading manufacturer of injection, primary container, and infusion therapy devices, has launched a pre-fillable polymer syringe for low dose applications such as ophthalmic drugs.<br></p> |
